Nachrichten zur Regeneron Pharmaceuticals Inc. Aktie

Regeneron Pharmaceuticals: Neue Coverage

New York (www.aktiencheck.de) - Rating-Update: William Pickering, Analyst von Sanford C. Bernstein & Co, nimmt die Coverage der Aktie von Regeneron…

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…

Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 44th Annual Health Care Conference Call Transcript

…

Regeneron Pharmaceuticals: Kursziel gesteigert

Toronto (www.aktiencheck.de) - Rating-Update: Die Analysten von RBC Capital Markets stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

Regeneron Pharmaceuticals: Kursziel erhöht

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Argus Research stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

Regeneron Pharmaceuticals, Inc. (REGN) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)

…

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

…

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2023 Earnings Call Transcript

…

Regeneron Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Regeneron Pharmaceuticals: Starke Quartalszahlen sorgen für ein sattes Kursplus - Unbedingt dabeibleiben! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Regeneron Pharmaceuticals Inc.…

AKTIONÄR-Top-Tipp Regeneron: Bockstarke Zahlen – magische Marke geknackt

Noch nie stand die Aktie von Regeneron Pharmaceuticals über der magische Marke von 1.000,00 Dollar. Am Freitag dieser Handelswoche notiert…

Regeneron Pharmaceuticals beats top-line and bottom-line estimates; initiates FY24 outlook

…

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for…

Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency…

Melanoma Drugs - $13.98 Billion Industry Opportunity Assessment, 2024-2028: Regional Insights and Competitor Market Shares

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Melanoma Drugs Global Market Report 2024" report has been added…

Regeneron Pharmaceuticals: Kurszielerhöhung

London (www.aktiencheck.de) - Rating-Update: Barclays stuft die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol: RGO, NASDAQ-Symbol: REGN) weiterhin…

Regeneron Pharmaceuticals: Neues Kursziel

Minneapolis (www.aktiencheck.de) - Rating-Update: Christopher Raymond, Analyst von Piper Sandler, bekräftigt das Rating "overweight" für die Aktie von Regeneron Pharmaceuticals Inc.…

Regeneron Pharmaceuticals: Schätzungen und Kursziel angehoben - Aktienanalyse

New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Morgan Stanley: Die Analysten von Morgan Stanley heben in einer aktuellen Aktienanalyse ihr Kursziel…

Bull of the Day: Regeneron Pharmaceuticals (REGN)

The Biotechnology company enjoys a litany of bullish catalysts on the horizon…

Regeneron Pharmaceuticals: Rückenwind durch positiven Analystenkommentar - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Heres Why Regeneron Just Hit A Record High

Theres more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.…

Regeneron Pharmaceuticals: Upgrade wegen besserer Transparenz - Aktienanalyse

Toronto (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von RBC Capital Markets: Brian Abrahams, Analyst vom Investmenthaus RBC Capital Markets, stuft die Aktie von…

Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)

…

Regeneron hints at 4Q US sales of Eylea below expectations

Regeneron Pharmaceuticals (NASDAQ:REGN) shares fell over 3% in early Monday afternoon trading after it told investors that US net product sales…

Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024

TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will…

Regeneron Pharmaceuticals: Gute Nachricht - Aktienanalyse

New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Goldman Sachs: Salveen Richter, Analystin von Goldman Sachs, rät in einer aktuellen Aktienanalyse weiterhin…

Regeneron Pharmaceuticals: Kurszielanhebung

New York (www.aktiencheck.de) - Rating-Update: Oppenheimer bewertet die Aktie von Regeneron Pharmaceuticals (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol: RGO, NASDAQ-Symbol: REGN) weiterhin…

Regeneron Pharmaceuticals: Positive gerichtliche Neuigkeiten - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Regeneron: Wichtiger Erfolg - Aktie auf Rekordjagd

Am Mittwoch ist die Aktie von Regeneron Pharmaceuticals im Handelsverlauf auf ein neues Rekordhoch gestiegen. Allerdings handelt es sich bei…

Regeneron: Wichtiger Erfolg – Aktie auf Rekordjagd

Am Mittwoch ist die Aktie von Regeneron Pharmaceuticals im Handelsverlauf auf ein neues Rekordhoch gestiegen. Allerdings handelt es sich bei…

Regeneron Gains After Eye-Drug Patent Victory Over Viatris

Regeneron Pharmaceuticals Inc. rose the most since August after a court ruled that the drugmaker’s patent rights were infringed by…

Where Will Regeneron Pharmaceuticals Be in 1 Year? @themotleyfool #stocks $REGN

Can the stock continue its market-beating ways?…

Where Will Regeneron Pharmaceuticals Be in 1 Year?

Can the stock continue its market-beating ways?…

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at…

Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market

Shares of Regeneron Pharmaceuticals Inc. sank 0.01% to $876.00 Thursday, on what proved to be an all-around favorable trading session…

Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript)

…

Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

The STRIDE study did not meet its primary or secondary efficacy endpoint…

Regeneron Pharmaceuticals: Neues Kursziel

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Morgan Stanley stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

Top 5 NASDAQ Genetics Stocks of 2023

The genetics sector supports every other life science industry in a variety of ways.One of its major contributions is the…

Top 5 NASDAQ Genetics Stocks (Updated March 2023)

The genetics sector supports every other life science industry in a variety of ways.One of its major contributions is the…

Regeneron Pharmaceuticals: Kursziel verbessert

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von TD Cowen stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

: Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals

Replimune Group Inc. shares REPL dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer…

Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 35th Annual Healthcare Conference (Transcript)

…

Regeneron Pharmaceuticals: Positive Ergebnisse aus der zweiten Phase-3-Studie für Dupixent - Aktienanalyse

New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Jefferies & Co: Akash Tewari, Analyst von Jefferies & Co, stuft die Aktie von…

Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study

Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…

dpa-AFX ProFeed